Paul M Barr

37PUBLICATIONS
162CO-AUTHORS
OtorhinolaryngologyHaematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Jul 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Jan A Burger, Paul M Barr, Tadeusz Robak

|Jun 06, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Jeff P Sharman, Talha Munir, Sebastian Grosicki

|Jan 02, 2025
Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.

Jennifer E Bruno, Christine A Herne, Andrea M Baran

|Feb 06, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.

Michael L Wang, Jacqueline C Barrientos, Richard R Furman

|Jan 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.

Jennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert

|Oct 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.

Brian T Hill, Shuo Ma, Clive S Zent

Pageof 7

Frequent Collaborators

8 joint publications

John N Allan

6 joint publications

Paolo Ghia

5 joint publications

Clive S Zent

4 joint publications

Harry Erba